ARTICLE | Financial News

Ambit files for IPO

November 9, 2010 1:15 AM UTC

Ambit Biosciences Corp. (San Diego, Calif.) filed to raise up to $86.3 million in an IPO underwritten by JPMorgan; Credit Suisse; Wedbush; and Leerink. Ambit's lead candidate, quizartinib, is an oral small molecule FMS-like tyrosine kinase 3 ( FLT3) inhibitor in Phase II testing for acute myelogenous leukemia (AML). ...